Daraxonrasib extends median overall survival to 13.2 months compared with 6.7 months for standard chemotherapy in advanced pancreatic cancer patients, according to Nebraska Medicine.
The Food and Drug Administration approved daraxonrasib in August as an oral pill taken once daily. The therapy interferes with the RAS signaling pathway, which acts as a cellular growth switch. Nebraska Medicine reported that abnormal RAS activity drives more than 90 percent of pancreatic ductal adenocarcinomas.
“Pancreatic cancer can be aggressive and hard to treat, so a therapy that may improve outcomes is exciting,” said Christina Hoy, DNP, clinical program director of the Pancreatic Diseases Specialty Clinic at Nebraska Medicine.
The phase 3 RASolute 302 trial evaluated daraxonrasib against standard chemotherapy in patients whose pancreatic cancer progressed following prior treatment. Trial data showed that participants receiving daraxonrasib achieved a median overall survival of 13.2 months. Patients treated with standard chemotherapy recorded a median overall survival of 6.7 months.
Progression-free survival favored the targeted pill over standard chemotherapy. Patients taking daraxonrasib went a median of 7.2 months before their cancer grew. The standard chemotherapy group experienced a median progression-free duration of 3.6 months.
“These results cannot predict what will happen for each patient,” Hoy told Nebraska Medicine. “Still, they show that targeting RAS can make a real difference.”
Traditional chemotherapy impacts multiple rapidly dividing cells across the body. In contrast, daraxonrasib targets the RAS signaling pathway directly implicated in tumor proliferation. Researchers are currently evaluating the drug earlier in treatment protocols and alongside combination regimens.
Eligibility decisions depend on individual patient evaluations. Clinical teams assess previous treatments, general health status, functional daily capacity, laboratory markers, and specific tumor characteristics.
Patients taking the oral medication still require routine clinical visits and laboratory monitoring. Common side effects involve rash, diarrhea, nausea, and mouth inflammation or soreness. Early detection allows clinical teams to manage complications promptly.
“If we find problems early, we can often treat them before they get worse,” Hoy told Nebraska Medicine. “We want patients to stay on treatment when it helps and have the best quality of life possible.”
Delivering the therapy at the Fred & Pamela Buffett Cancer Center enables patients to remain near their support systems while receiving specialized oncology care.
The drug blocks the RAS signaling pathway, which functions as an active switch controlling cell growth and division. Over 90 percent of pancreatic ductal adenocarcinomas exhibit abnormal RAS activity that drives tumor survival.
Patients should confirm whether their tumor underwent appropriate molecular testing and inquire about eligibility for targeted therapies or clinical trials. Appointments with pancreatic cancer specialists at the center can be scheduled by calling 844.CUR.PANC.
Related reading